O'Neill: UK 'Lost Focus' On Antibiotic Crisis And Pharma Must Do More
Executive Summary
The time for talking is over when it comes to antimicrobial resistance, says Jim O'Neill, urging the government to 'rediscover the passion for championing' initiatives in the UK, notably the new AMR Centre in Alderley Park near Manchester.
You may also be interested in...
Podcast: Will A ‘Netflix’ Model Solve Antibiotic Reimbursement Challenges And Spur R&D?
Infex CEO Peter Jackson discusses the state of antimicrobial resistance in the UK, and globally. He highlights the potential of a new “Netflix” style subscription model for antibiotic reimbursement, as well as future challenges for biotechs in the anti-infectives space.
New Report Calls For Pushing And Pulling In Global Fight Against Superbugs
New DRIVE-AB report on revitalizing antibiotic R&D suggests market-entry rewards of up to $1bn for companies introducing novel products, cites need for increasing public funding of R&D support.
O'Neill Warns Pharma Risks Backlash If Doesn't Engage In World AMR Pact
The globalized drugs industry needs to play ball and help find a solution to antimicrobial resistance or risk getting blamed for its failure and the resulting world health crisis.